Business context and reporting period
This filing is enGene Holdings Inc.’s Form 10-K for the fiscal year ended October 31, 2023—not a separate calendar fourth-quarter report. Although the request names Engene Therapeutics Inc., the registrant identified in the filing is enGene Holdings Inc., a Canadian clinical-stage biotechnology company developing non-viral gene therapies using its DDX delivery platform. Its lead candidate, EG-70, is being studied for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company completed its reverse recapitalization with Forbion European Acquisition Corp. on October 31, 2023; shares began trading on Nasdaq on November 1, 2023.
Financial and operating highlights
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $16.5 million | $15.5 million |
| General and administrative expense | $9.6 million | $4.0 million |
| Operating loss | $26.1 million | $19.4 million |
| Net loss | $99.9 million | $24.5 million |
| Net cash used in operating activities | $24.7 million | $17.6 million |
| Net cash used in investing activities | $0.3 million | $0.2 million |
| Net cash provided by financing activities | $86.1 million | $28.0 million |
At October 31, 2023, cash and cash equivalents were $81.5 million, total assets $87.0 million, total liabilities $14.5 million, and shareholders’ equity $72.5 million. The Hercules term loan was the only debt outstanding at year-end; its net carrying value was $9.8 million. The filing reports a basic and diluted net loss per share of $151.22, using a retrospectively adjusted weighted-average share count of 692,609 following the reverse recapitalization. Profit margins are not meaningful because the company had no revenue.
The $99.9 million net loss included substantial non-cash fair-value and financing items: $56.2 million from changes in the fair value of convertible debentures and $21.4 million from embedded derivative liabilities. These instruments were converted or settled in connection with the October 31 transaction; the reported loss therefore substantially exceeded the $26.1 million operating loss.
Changes versus the prior comparable period
- Net loss rose by $75.5 million year over year, driven primarily by fair-value charges and extinguishment-related items, rather than a comparable increase in operating costs.
- Operating expenses increased $6.6 million. R&D rose $1.0 million, while G&A increased $5.6 million, including higher share-based compensation and public-company accounting and audit costs.
- Operating cash use increased $7.2 million. Financing cash flow increased following convertible note issuances and the reverse recapitalization/PIPE financing.
- Cash increased from $20.4 million to $81.5 million, supported by financing. The company also changed its functional currency from the Canadian dollar to the U.S. dollar effective November 1, 2022; prior-year statements were not restated for that change.
Outlook, commentary, and principal risks
Management expects continued operating losses and says additional funding will be required. It estimated that year-end cash together with the December 2023 Hercules facility, including the $22.5 million initial advance, would fund planned expenses and debt service into the second quarter of 2025. This estimate excludes potential milestone-based loan tranches and depends on assumptions about clinical-development costs and timing. The audited statements and auditor’s report state that recurring losses, negative operating cash flows, and the need for additional financing raise substantial doubt about the company’s ability to continue as a going concern.
- Clinical program: LEGEND is an open-label Phase 1/2 study of EG-70. In Phase 1, 15 of 22 evaluable patients had a complete response at three months (68%); the filing also reports a best overall complete-response rate of 16 of 22 (73%). In the selected dose cohort, 7 of 10 patients had a three-month complete response and 6 of 10 had a six-month response after electing to continue treatment. Phase 1 was designed primarily to assess safety and was not powered to establish efficacy statistically. The company aims to file a U.S. BLA in 2025, subject to further trial results and regulatory review.
- Pipeline: EG-i08 is in preclinical development for cystic fibrosis; candidate nomination was expected in 2024, subject to technical and funding assessments. The filing also describes plans to explore EG-70 in other indications, which remain developmental plans rather than established milestones.
- Financing and debt: In December 2023, the company amended and restated its Hercules agreement into a facility of up to $50 million, with $22.5 million initially advanced and additional tranches subject to conditions. The facility carries cash interest and payment-in-kind interest, is secured by company assets subject to exceptions, and imposes restrictive covenants, including a minimum-liquidity covenant beginning in October 2024, subject to extensions or adjustments under specified conditions.
- Controls and reporting: Management concluded disclosure controls were ineffective as of year-end and identified unremediated material weaknesses in financial reporting controls, staffing and GAAP expertise, IT controls, and segregation of duties. Management described remediation plans but gave no assurance of timely or successful remediation.
- Other key risks: No approved products or product revenue; need for further capital; clinical, regulatory, manufacturing and enrollment uncertainty; dependence on external manufacturers and research providers; competition; reimbursement uncertainty; and intellectual-property risks. The company reported no legal proceedings expected to have a significant negative effect. Its registered-share resale overhang and the potential for dilution are also disclosed; warrants have an $11.50 exercise price and may expire worthless.
Important facts for investors to verify
- Whether LEGEND enrollment, follow-up, safety, and Phase 2 efficacy results support the planned 2025 BLA timetable; distinguish exploratory Phase 1 response results from pivotal evidence.
- Whether the stated cash runway remains achievable after actual operating burn, trial costs, debt service, and any conditions attached to Hercules tranches.
- The current debt balance, interest and payment-in-kind accruals, covenant compliance, and available unrestricted liquidity under the amended Hercules agreement.
- Progress and independent validation of remediation of the disclosed material weaknesses and ineffective disclosure controls.
- The impact of registered resales, warrant exercises, equity-plan awards, and other potential share issuance on dilution and market supply.
- The reported $151.22 loss per share and share-count presentation, given the reverse recapitalization and retrospective exchange-ratio adjustments.